Freenome’s updated SimpleScreen CRC blood test met primary and secondary endpoints in a large clinical validation study drawn from the prospective PREEMPT CRC registry and additional blinded samples. The company reported overall sensitivity of 80.4% and specificity of 90%, with improved detection metrics for advanced precancerous lesions compared with its prior version. While reactions were mixed, the study’s scale—48,995 average-risk adults aged 45 to 85 scheduled for colonoscopy—keeps the test in the spotlight as blood-based screening moves from concept toward operational validation.